PEPTIC ULCER DRUGS MARKET ANALYSIS

Peptic Ulcer Drugs Market, by Product Type (Proton Pump Inhibitors, Potassium-Competitive Acid Blocker (P-CAB), Antacids, H2- Antagonist, Antibiotics, Ulcer Protective) by Disease Indication (Gastitis, Gastric Ulcer, Duodenal Ulcer, Gastroesophageal Reflux Disease (GERD)), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Published In : May 2023
Code : CMI3246
Pages :204
Formats :
Excel and PDF
Industry : Pharmaceutical

Market News

Global Peptic Ulcer Drugs Market: Key Developments

In August 2021, the Subject Matter Expert Committee (SEC) functioning under CDSCO recommended Sun Pharma conduct a phase 3 clinical trial of esomeprazole dual-release gastro-resistant tablets 80mg vs esomeprazole gastro-resistant tablets 40mg bids for the proposed indication.

In August 2021, Dr. Reddy's Laboratories, a pharmaceutical company, announced the launch of generic Chlordiazepoxide Hydrochloride and Clidinium Bromide capsules for the treatment of stomach ulcers, irritable bowel syndrome, and colon inflammation.

In May 2020, researchers from the Michael E. De-Bakey Veterans Affairs Medical Center received U.S. FDA approval for the three drug combination of omeprazole, amoxicillin and rifabutin in one capsule, RHB-105 for treatment of Helicopter pylori infections in adults.

In May 2020, Daewoong Pharmaceutical, a pharmaceutical company, announced for the first time the phase 3 clinical data of Fexuprazan, a novel gastroesophageal reflux disease agent at Digestive Disease Week (DDW) 2020. The abstract of Fexuprazan has been rated in the top 10% posters of all American Gastroenterological Association (AGA) abstracts selected for poster presentation and selected as a Poster of Distinction for presentation during Digestive Disease Week.

In October 2021, RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced the granting of U.S. Patent No. 11,135,172 covering Talicia, its U.S. approved medicine indicated for the treatment of H. pylori infection in adults.